03:46 PM EST - RepliCel Life Sciences Inc. : Has received approval from the Paul Ehrlich Institute (PEI), the regulatory body responsible for approving all cell-based clinical trials in Germany, to conduct its RCS-01 skin rejuvenation clinical trial. PEI approval clears the way for site initiation and patient recruitment to be conducted at the IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in Germany. RepliCel Life Sciences Inc.
shares V.RP are trading down $0.025 at $0.38.
